29 Sep Arrowhead Pharmaceuticals inks drug development deal with Amgen worth up to $673 million
Amgen, one of the world's leading biotechnology companies, is teaming with Arrowhead Pharmaceuticals to bring two drugs to market to treat cardiovascular disease in a deal worth more than $50 million to start with the potential for another $600 million or more in the future....